Get the Stockscreener App
4.29
2.39%
0.10
After Hours:
4.28
-0.010
-0.23%
Arbutus Biopharma Corp Stock (ABUS) Forecast
The Arbutus Biopharma Corp (ABUS) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $3.7501, representing a -12.59% decrease from the current price of $4.29. The highest analyst price target is $4.325, and the lowest is $3.1751.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ABUS Price Target
Average 4.3805
(+2.11% Upside)
Is Arbutus Biopharma Corp (ABUS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 37.64 | Neutral |
| STOCH(9,6) | 17.19 | Buy |
| STOCHRSI(14) | 71.49 | Neutral |
| MACD(12,26) | -0.2029 | Sell |
| ADX(14) | 32.02 | Sell |
| William %R | -73.33 | Neutral |
| CCI(14) | -34.73 | Neutral |
Buy: 1
Sell: 2
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
4.303
Sell
|
4.3247
Sell
|
| MA20 |
4.576
Sell
|
4.5015
Sell
|
| MA50 |
4.8114
Sell
|
4.6695
Sell
|
| MA100 |
4.6687
Sell
|
4.6506
Sell
|
| MA200 |
4.522
Sell
|
4.5072
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, ABUS could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 12 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on ABUS, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 37.64 indicates that ABUS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 17.19 indicates that ABUS is oversold. This indicates that ABUS price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 71.49 indicates that ABUS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 32.02 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -34.73 indicates that ABUS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term ABUS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Arbutus Biopharma Corp financial reports and earnings history, Arbutus Biopharma Corp (ABUS) stock could reach $4.8939 by 2030, $3.0068 by 2040 and $3.5086 by 2050. See the projected annual prices until 2050 of the Arbutus Biopharma Corp stock below:
- Arbutus Biopharma Corp (ABUS) is expected to reach an average price of $3.0963 in 2035, with a high prediction of $3.1263 and a low estimate of $2.5461. This indicates an $-27.83% rise from the last recorded price of $4.29.
- Arbutus Biopharma Corp (ABUS) stock is projected to chart a bullish course in 2040, with an average price target of $2.6721, representing an $-37.71% surge from its current level. The forecast ranges from a conservative $2.6521 to a sky-high $3.0068.
- Our analysts predict Arbutus Biopharma Corp (ABUS) to jump -21.30% by 2045, soaring from $2.9261 to an average price of $3.3763, potentially reaching $3.496. While $2.9261 is the low estimate, the potential upside is significant.
- Arbutus Biopharma Corp (ABUS) stock is expected to climb by 2050, reaching an average of $3.309, a $-22.87% jump from its current level. However, a wide range of estimates exists, with high and low targets of $3.5086 and $2.7588, respectively, highlighting the market's uncertainty.
Arbutus Biopharma Corp Stock (ABUS) Year by Year Forecast
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2026
The predicted value for Arbutus Biopharma Corp (ABUS) in 2026 is set at an average of $4.9201. Estimates vary from a peak of $6.6652 to a trough of $3.1751, indicating an +14.69% surge from the present price of $4.29.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2026 | $3.3651 | $3.1751 | $4.325 | -21.56% |
| December, 2026 | $4.3252 | $3.7052 | $6.6652 | +0.82% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Arbutus Biopharma Corp (ABUS) is $3.1708, with a high forecast of $4.3253 and a low forecast of $2.0163. This indicates an -26.09% decrease from the last price of $4.29.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.8453 | $2.7953 | $4.3253 | -33.68% |
| February, 2027 | $3.3254 | $2.5453 | $3.6354 | -22.48% |
| March, 2027 | $3.0755 | $2.8555 | $3.8055 | -28.31% |
| April, 2027 | $3.2456 | $2.9406 | $3.3256 | -24.34% |
| May, 2027 | $2.6957 | $2.4257 | $3.3856 | -37.16% |
| June, 2027 | $2.5958 | $2.0958 | $2.6758 | -39.49% |
| July, 2027 | $3.0059 | $2.4559 | $3.1159 | -29.93% |
| August, 2027 | $2.556 | $2.556 | $3.156 | -40.42% |
| September, 2027 | $2.4461 | $2.3561 | $2.746 | -42.98% |
| October, 2027 | $2.4062 | $2.2762 | $2.5652 | -43.91% |
| November, 2027 | $2.3563 | $2.0163 | $2.6062 | -45.07% |
| December, 2027 | $2.7164 | $2.2064 | $2.7864 | -36.68% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2028
In 2028, Arbutus Biopharma Corp (ABUS) is projected to reach an average price of $2.6805, with a high projection of $3.312 and a low estimate of $2.0491. This indicates an -37.52% fall from the last price of $4.29.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $2.6465 | $2.4265 | $3.0765 | -38.31% |
| February, 2028 | $2.4966 | $2.3666 | $2.9736 | -41.80% |
| March, 2028 | $3.0967 | $2.3167 | $3.1367 | -27.82% |
| April, 2028 | $2.9068 | $2.7818 | $3.1968 | -32.24% |
| May, 2028 | $3.1569 | $2.7369 | $3.2469 | -26.41% |
| June, 2028 | $3.037 | $2.967 | $3.312 | -29.21% |
| July, 2028 | $2.7371 | $2.5871 | $3.2045 | -36.20% |
| August, 2028 | $2.6622 | $2.5772 | $2.8872 | -37.94% |
| September, 2028 | $2.4273 | $2.3573 | $2.6922 | -43.42% |
| October, 2028 | $2.3074 | $2.1624 | $2.4873 | -46.21% |
| November, 2028 | $2.1975 | $2.1475 | $2.3175 | -48.78% |
| December, 2028 | $2.0976 | $2.0491 | $2.3776 | -51.10% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2029
The 2029 price forecast for Arbutus Biopharma Corp Stock (ABUS) is $3.0032 on average, with a high prediction of $4.1487 and a low estimate of $1.8577. This represents an -29.99% decrease from the previous price of $4.29.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.8977 | $1.8577 | $2.2176 | -55.76% |
| February, 2029 | $2.0278 | $1.8678 | $2.1378 | -52.73% |
| March, 2029 | $2.2379 | $1.9578 | $2.2579 | -47.83% |
| April, 2029 | $2.478 | $2.1479 | $2.798 | -42.24% |
| May, 2029 | $2.5481 | $2.378 | $2.7181 | -40.60% |
| June, 2029 | $2.9682 | $2.4931 | $3.1282 | -30.81% |
| July, 2029 | $2.7483 | $2.5883 | $2.9782 | -35.94% |
| August, 2029 | $2.8984 | $2.4683 | $3.4583 | -32.44% |
| September, 2029 | $3.1485 | $2.7985 | $3.1785 | -26.61% |
| October, 2029 | $3.2186 | $3.0836 | $3.8086 | -24.97% |
| November, 2029 | $3.8587 | $3.1136 | $4.0587 | -10.05% |
| December, 2029 | $3.8788 | $3.4688 | $4.1487 | -9.58% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2030
Arbutus Biopharma Corp Stock (ABUS) is expected to reach an average price of $3.8843 in 2030, with a high forecast of $4.8939 and a low forecast of $2.8747. This signifies an -9.46% decrease from the last price of $4.29.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $4.6389 | $3.8517 | $4.8939 | +8.13% |
| February, 2030 | $4.009 | $3.819 | $4.7089 | -6.55% |
| March, 2030 | $4.0141 | $3.849 | $4.5182 | -6.43% |
| April, 2030 | $3.6292 | $3.5542 | $4.1594 | -15.40% |
| May, 2030 | $3.3793 | $3.2793 | $3.9593 | -21.23% |
| June, 2030 | $3.3694 | $3.2993 | $3.7094 | -21.46% |
| July, 2030 | $3.5895 | $3.3294 | $3.7845 | -16.33% |
| August, 2030 | $3.4496 | $3.1896 | $3.8695 | -19.59% |
| September, 2030 | $3.3197 | $2.8747 | $3.7797 | -22.62% |
| October, 2030 | $3.3998 | $3.2547 | $3.8948 | -20.75% |
| November, 2030 | $3.6499 | $3.1098 | $3.7049 | -14.92% |
| December, 2030 | $3.41 | $3.21 | $3.82 | -20.51% |
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):